Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits

Individuals with haemophilia B require replacement therapy with recombinant or plasma‐derived coagulation factor IX (fIX). More benefit per injected dose might be obtained if fIX clearance could be slowed. The contribution of overall size to fIX clearance was explored, using genetic fusion to albumin. Recombinant murine fIX (MIX), and three proteins with C‐terminal epitope tags were expressed in HEK 293 cells: tagged MIX (MIXT), tagged mouse serum albumin (MSAT) and MFUST, in which MIX and MSAT were fused in a single polypeptide chain. Proteins MFUST and MIXT were two‐ to threefold less active in clotting assays than MIX. In mice, the area under the clearance curve (AUC) was reduced for MFUST compared with MSAT or plasma‐derived MSA (pd‐MSA); the terminal catabolic half‐life (t0·5) did not differ amongst the three proteins. Two minutes after injection, >40% of the injected MFUST was found in the liver, compared with <10% of either MSAT or pd‐MSA. In rabbits, the AUC for MFUST was reduced compared to MIXT, MSAT, or pd‐MSA, while the t0·5 of the fusion protein fell between that of MIXT and MSAT or pd‐MSA. Similar results were obtained with non‐radioactive fused or non‐fused recombinant human fIX in fIX knockout mice. The clearance behaviour of the fusion protein thus more closely resembled that of fIX than that of albumin despite a modest increase in terminal half‐life, suggesting that fIX‐specific interactions that are important in determining clearance were maintained in spite of the increased size of the fusion protein.

[1]  M. A. Rothschild,et al.  Serum albumin , 2005, The American Journal of Digestive Diseases.

[2]  W. Sheffield,et al.  A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin. , 2004, The Journal of laboratory and clinical medicine.

[3]  M. Kay,et al.  A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. , 2003, Blood.

[4]  C. Négrier,et al.  The P‐selectin cytoplasmic domain directs the cellular storage of a recombinant chimeric factor IX , 2003, Journal of thrombosis and haemostasis : JTH.

[5]  K. Loeb,et al.  Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high‐expressing human factor IX plasmid , 2003, Journal of thrombosis and haemostasis : JTH.

[6]  M. Haase.  Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2002, Blood.

[7]  Tong Gui,et al.  Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. , 2002, Blood.

[8]  D. Lillicrap,et al.  Recombinant Factor IX Recovery and Inhibitor Safety: A Canadian Post-licensure Surveillance Study , 2002, Thrombosis and Haemostasis.

[9]  C. Leissinger,et al.  Pharmacokinetic analysis of plasma‐derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B , 2002, Transfusion.

[10]  V. Bhakta,et al.  A Barbourin-albumin Fusion Protein that Is Slowly Cleared In Vivo Retains the Ability to Inhibit Platelet Aggregation In Vitro , 2001, Thrombosis and Haemostasis.

[11]  V. Bhakta,et al.  Prolonged in vivo anticoagulant activity of a hirudin–albumin fusion protein secreted from Pichia pastoris , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[12]  D. Gabriel,et al.  Location of the platelet binding site in zymogen coagulation factor IX , 2001, Blood Coagulation and Fibrinolysis.

[13]  W. Sheffield.  Modification of clearance of therapeutic and potentially therapeutic proteins. , 2001, Current drug targets. Cardiovascular & haematological disorders.

[14]  G. Hortelano,et al.  Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  P. Lenting,et al.  Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. , 2000, Blood.

[16]  V. Bhakta,et al.  Modulation of clearance of recombinant serum albumin by either glycosylation or truncation. , 2000, Thrombosis research.

[17]  V. Ananthanarayanan,et al.  Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. , 2000, Thrombosis research.

[18]  O. Christophe,et al.  Surface Loop 199–204 in Blood Coagulation Factor IX Is a Cofactor-dependent Site Involved in Macromolecular Substrate Interaction* , 1999, The Journal of Biological Chemistry.

[19]  W. Bode,et al.  Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity* , 1998, The Journal of Biological Chemistry.

[20]  J. Rouse,et al.  Biochemical characterization of recombinant factor IX. , 1998, Seminars in hematology.

[21]  M. Zoppè,et al.  A factor IX-deficient mouse model for hemophilia B gene therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Sheffield,et al.  Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. , 1997, Blood.

[23]  H. Pettersson,et al.  Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.

[24]  A. Wolberg,et al.  Factor IX activation by factor XIa proceeds without release of a free intermediate. , 1997, Biochemistry.

[25]  R. Schaub,et al.  Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. , 1996, Blood.

[26]  E. Berntorp.  The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. , 1996, Bailliere's clinical haematology.

[27]  B. Misra,et al.  Evaluation of Recombinant Human Factor IX: Pharmacokinetic Studies in the Rat and the Dog , 1995, Thrombosis and Haemostasis.

[28]  K. Berkner.  Expression of recombinant vitamin K-dependent proteins in mammalian cells: factors IX and VII. , 1993, Methods in enzymology.

[29]  H. Breddin.  Pathophysiology of thromboembolism and its modulation by low molecular weight heparins. , 1993, Seminars in thrombosis and hemostasis.

[30]  A. Thompson.  Factor IX concentrates for clinical use. , 1993, Seminars in thrombosis and hemostasis.

[31]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[32]  D. Landais,et al.  Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Mcclure,et al.  Characterization and Novel Purification of Recombinant Human Protein C from Three Mammalian Cell Lines , 1990, Bio/Technology.

[34]  K. J. van der Merwe,et al.  Improvements in the isolation of IgY from the yolks of eggs laid by immunized hens. , 1985, Immunological investigations.

[35]  L. Suzuki,et al.  Factor IX antigen by a rapid staphylococcal protein A‐membrane binding radioimmunoassay: results in haemophilia B patients and carriers and in fetal samples , 1982, British journal of haematology.

[36]  D. Rees,et al.  Molecular cloning of the gene for human anti-haemophilic factor IX , 1982, Nature.

[37]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[38]  A. Babson,et al.  Comparative evaluation of a partial thromboplastin reagent containing a non-settling, particulate activator. , 1974, American journal of clinical pathology.